Results of the REVEAL study. Why Should we not welcome a new lipid lowering agent?

Luis Masana

Journal: Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis 2018;29(6):278-279

PMID: 29173491

Full Text on Elsevier Science View on PubMed

Abstract

Address: Unitat de Medicina Vascular i Metabolisme, Hospital Universitari Sant Joan, Universitat Rovira I Virgili, IISPV, CIBERDEM, Reus, Tarragona, España. Electronic address: [email protected].

DOI: 10.1016/j.arteri.2017.10.002

Link outs

Free resources

Medical:

https://medlineplus.gov/cholesterolmedicines.html

Other Literature Sources:

https://scite.ai/reports/29173491

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S0214...

MeSH Terms: Cardiovascular Diseases, Cholesterol, LDL, Humans, Hypolipidemic Agents, Lipids, Oxazolidinones, Randomized Controlled Trials as Topic